Keyword: Mark Alles

Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.

Bristol-Myers is counting on new talent from Novartis and Celgene—and a revamped R&D chart—to buck up its existing drugs and new launches.

Analysts pounded the CEOs of BMS and Celgene for details about their integration plans. But investors seemed dissatisfied with their answers.

With resolutions on the ballot at six top U.S. drugmakers, investors aim to learn how drug pricing affects executive pay.

The early FDA nod for Soliris follow-up Ultomiris and a new pricing strategy helped Alexion CEO Ludwig Hantson get $16.5 million in 2018.

Celgene said CEO Mark Alles hit financial and regulatory milestones to win a hefty 2018 bonus, but investors were focused on the company's troubles.

Celgene's recently adopted change-in-control severance system could pay off big time for Celgene CEO Mark Alles and three other top executives.

Celgene's Revlimid cleared a big hurdle as the U.S. Patent and Trademark office declined to kick off a review of its patents.

On Dec. 10, Bristol-Myers Squibb made what it said was its final offer to buy Celgene. But it ended up striking a better deal instead.